| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CIDEA |
| Uniprot No | O60543 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-219aa |
| 氨基酸序列 | MEAARDYAGA LIRPLTFMGS QTKRVLFTPL MHPARPFRVS NHDRSSRRGV MASSLQELIS KTLDALVIAT GLVTLVLEED GTVVDTEEFF QTLGDNTHFM ILEKGQKWMP GSQHVPTCSP PKRSGIARVT FDLYRLNPKD FIGCLNVKAT MYEMYSVSYD IRCTGLKGLL RSLLRFLSYS AQVTGQFLIY LGTYMLRVLD DKEERPSLRS QAKGRFTCG |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CIDEA重组蛋白的3篇代表性文献摘要整理：
1. **《CIDEA regulates lipid droplet formation in adipocytes》**
作者：Zhou, L. et al.
摘要：研究利用重组CIDEA蛋白揭示了其在脂肪细胞脂滴形成中的关键作用，通过体外实验证明CIDEA通过调控脂质表面张力促进脂滴融合。
2. **《Structural insights into CIDEA-mediated apoptosis》**
作者：Purcell, M. et al.
摘要：通过重组CIDEA蛋白的晶体结构解析，发现其C端结构域通过与线粒体膜蛋白互作诱导细胞凋亡，为代谢疾病治疗提供了靶点依据。
3. **《Recombinant CIDEA exacerbates hepatic steatosis in obesity models》**
作者：Petersen, R.K. et al.
摘要：在小鼠模型中注射重组CIDEA蛋白后，观察到肝脏脂质沉积显著增加，证实其在肥胖相关脂肪肝病理中的促进作用。
(注：上述文献信息为示例性概括，实际研究中建议通过PubMed/Web of Science以"CIDEA recombinant protein"为关键词检索最新文献)
**Background of CIDEA Recombinant Protein**
CIDEA (Cell Death-Inducing DFFA-like Effector A) is a protein encoded by the *CIDEA* gene, belonging to a family of cell death-inducing proteins involved in apoptosis and metabolic regulation. It is highly expressed in adipocytes and plays critical roles in lipid metabolism, thermogenesis, and energy homeostasis. CIDEA interacts with lipid droplets and mitochondrial membranes, influencing lipid storage, lipolysis, and mitochondrial uncoupling processes. In white adipose tissue, CIDEA suppresses lipid oxidation by inhibiting the activity of adipose triglyceride lipase (ATGL), promoting fat storage. Conversely, in brown and beige adipose tissue, CIDEA interacts with uncoupling protein 1 (UCP1), modulating thermogenic capacity and energy dissipation. Dysregulation of CIDEA is linked to metabolic disorders, including obesity, insulin resistance, and type 2 diabetes, making it a potential therapeutic target.
Recombinant CIDEA protein, produced via genetic engineering in bacterial or mammalian expression systems, retains the functional properties of native CIDEA. It enables *in vitro* studies to dissect its structural features, binding partners, and mechanistic roles in metabolic pathways. Researchers utilize recombinant CIDEA to investigate its dual role in apoptosis and metabolism, particularly its context-dependent pro- or anti-apoptotic effects in cancer cells. Additionally, it aids in exploring CIDEA’s involvement in adipocyte differentiation, mitochondrial dynamics, and cross-talk between metabolic tissues.
The development of CIDEA recombinant protein has advanced drug discovery efforts, facilitating high-throughput screening for compounds that modulate CIDEA activity. Its application extends to elucidating molecular pathways in metabolic diseases and cancer, offering insights for precision medicine strategies. Overall, CIDEA recombinant protein serves as a vital tool for unraveling the complex interplay between cell death, metabolism, and disease pathogenesis.
×
